Form 8-K - Current report:
SEC Accession No. 0001635088-26-000088
Filing Date
2026-08-06
Accepted
2026-08-06 07:13:50
Documents
12
Period of Report
2026-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K roiv-20260806.htm   iXBRL 8-K 26381
2 EX-99.1 q1fy2026roivantearningsrel.htm EX-99.1 117634
  Complete submission text file 0001635088-26-000088.txt   277751

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT roiv-20260806.xsd EX-101.SCH 1770
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT roiv-20260806_lab.xml EX-101.LAB 23237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT roiv-20260806_pre.xml EX-101.PRE 13516
15 EXTRACTED XBRL INSTANCE DOCUMENT roiv-20260806_htm.xml XML 2872
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 261245954
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)